MARATTO

article · Minia Journal of Medical Research

Study of Immunohistochemical Expression of NUSAP1 in Clear Cell Renal Cell Carcinoma

2024Open accessMinia University

Abstract

Introduction: Globally, renal cell carcinoma (RCC) is among the most prevalent malignancies. A mixture of genetic mutations and environmental influences are the main causes. NUSAP1 is an anti-apoptotic marker which enhances cellular invasion and migration via a variety of pathways, including PI3K/AKT/mTOR pathway. NUSAP1 has been shown to be significantly expressed in variety of tumours, but little is known about its implications in ccRCC. Aim of work: to assess the IHC expressions of NUSAP1 and investigate the relationship between NUSAP1 expression and various clinical and pathological characteristics of cases of ccRCC. Methods: Fifty tissue specimens of ccRCC were subjected to IHC staining procedure of NUSAP1 utilizing the avidin biotin-peroxidase method in conjunction with chromagen detection in order to look into how clinicopathological data and NUSAP1 expression relate to one another. Results: In 60% of instances, there was evidence of prominent NUSAP1 expression. A statistically positive correlation was observed between the expression of NUSAP1 and tumor stage (p=0.003), Fuhrman grade (p=0.022), and distant metastases (p=0.007). Conclusion: In ccRCC, NUSAP1 expression may be regarded as a negative predictive factor. Keywords: Renal cell carcinoma, NUSAP1, IHC. There is no conflict of interest among authors.

Research topics

  • Renal and related cancers
  • Renal cell carcinoma treatment

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/mjmr.2024.298247.1730

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.